ASH: Sickle Cell Treatment Decisions In The Post-Oxbryta, Genetic Medicine Era

Patients Have One Less Option Than A Year Ago

 
• By Mandy Jackson
  
Hematologists at ASH lamented the loss of Oxbryta for sickle cell patients (Shutterstock)

More from ASH

More from Scrip